Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03471351
Title Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab + Tenalisib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois 60637 United States Details
Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute, Detroit Michigan 48201 United States Details
University of Washington Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field